Pear Therapeutics (US)

On April 7, 2023, Pear Therapeutics Inc. and its wholly owned subsidiary, Pear Therapeutics (US), Inc. (collectively, the “Debtors”) each voluntarily filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the District of Delaware (Case Nos. 23-10429; 23-20430). The Debtors intend to pursue a sale of the business or assets under section 363 of the Bankruptcy Code.

Our hope is that our business and/or products will be purchased so that another company can provide them to patients. Pear Therapeutics is not accepting new prescriptions for its products, reSET®, reSET-O®, and Somryst®, nor will refills be dispensed at this time. We will attempt to keep our products available for patients who are already using the products for the duration of the current fill of their prescription, but there can be no assurance that we will be able to do so.

Additional information about the Company’s Chapter 11 case may be found on both the Company’s website,, or the website of the Company’s Bankruptcy Claims and Noticing Agent, Stretto, at; or by calling Stretto’s hotline at 855.944.1910 (for toll-free U.S. and Canada calls) or 714.252.6860 (for tolled international calls) or via email at

Watch the Video

Prescription Digital Therapeutics

Software to treat human disease

Prescription Digital Therapeutics, or PDTs, are software-based medicines. PDTs are designed to directly treat disease, tested for safety and efficacy in randomized clinical trials, evaluated by the FDA, and prescribed by healthcare providers. PDTs are designed and tested much like traditional prescription drugs with one distinction: rather than swallowing a pill or taking an injection, patients are treated with software.

Pear Therapeutics

The leader in Prescription Digital Therapeutics

At Pear, our mission is clear: we are pioneers in PDTs. Our cross-functional team operates at the intersection of biology and software technology. Pear discovers, develops, and delivers clinically validated software to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Every day, we push the boundaries of technology to transform medicine.

Pipeline & Platform

Multiple products, therapeutic areas, and development stages

We are developing PDTs to treat patients suffering from a range of serious diseases. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program.